Physician profile
Jennifer Le Ashley
NPI 1174243943
$2,504.66
in general payments reported to CMS, 2019-2025
26 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $852 · 2023: $971 · 2024: $462 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,034.40 | 2022-2025 | |
| Novo Nordisk INC | $187.99 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Ardelyx, INC. | $167.99 | 2022-2023 | Ibsrela |
| Cvrx, INC. | $148.69 | 2022 | |
| Janssen Biotech, INC. | $118.18 | 2022-2024 | Stelara, Simponi, Tremfya |
| Merck Sharp & Dohme LLC | $102.48 | 2023-2024 | Dificid |
| Astrazeneca Pharmaceuticals LP | $100.60 | 2023-2024 | Airsupra, Farxiga, Fasenra |
| Lilly USA, LLC | $93.47 | 2024-2025 | Zepbound, Mounjaro, Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.42 | 2022 | |
| Genzyme Corporation | $69.90 | 2023 | |
| Intra-Sana Laboratories | $54.75 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.00 | 2024-2025 | Caplyta |
| Redhill Biopharma INC. | $33.22 | 2023 | Talicia |
| Nestle Healthcare Nutrition INC. | $32.56 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.08 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $25.32 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $24.27 | 2025 | Rexulti |
| Halozyme INC | $23.54 | 2023 | |
| Axsome Therapeutics, INC. | $22.65 | 2025 | Auvelity |
| Antares Pharma, INC. | $19.60 | 2024 | Xyosted |
| Daiichi Sankyo INC. | $17.44 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.27 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.92 | 2024 | Bylvay |
| Pfizer INC. | $15.77 | 2024 | |
| Glaxosmithkline, LLC. | $13.97 | 2025 | Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $13.18 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ashley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.